CSCC/SRSN Medication Profile

Name/route/dose
/frequency of the
medication

Classification

0.9 % sodium chloride

fluid and electrolyte
solution saline flush 3 mL replenishment

Normal
Dosage
Range

Reason for
administration

Nursing considerations/ responsibilities associated

with the administration of the medication.
(common side effects to assess for, particulars
about how and when to give the drug, what needs
to be assessed before administration of the drug,
etc):

3 ml

Line Care

10-20 mg PO qDay
initially

Reduce LDL cholesterol

levels and reduce total
blood cholesterol levels.
Also produce a mild
increase in HDL level

Adverse effects: Redness, pain, or swelling at the injection site may occur,
swelling hands/ankles/feet, trouble breathing, muscle cramps/weakness.
Check visually for particles or discoloration and expiration date. Sodium
Chloride Injection, USP should be used with great care, if at all, in patients
with congestive heart failure, severe renal insufficiency, and in clinical states
in which there exists edema with sodium retention. If an adverse reaction
does occur, discontinue the infusion, evaluate the patient.
Restrict pt to a standard low-cholesterol diet before and during therapy,
perform baseline lipid profile before starting treatment to exclude secondary
causes of hypercholesterolemia. Should be administered 1 hr before or 4 hrs.
after bile-sequestering drugs. May alter liver function studies, increasing
AST, ALT, ALP, and bilirubin levels. May cause joint pain. Assess pts
cholesterol levels and pruritus before therapy. Monitor blood cholesterol and
lipid levels. Monitor CK levels, liver function tests.
Monitor for adverse effects such as hypoglycemia and hypersensitivity
reactions. Monitor glucose level. Adverse effects include hypoglycemia,
somogyi effect, hypersensitivity reactions, lipodystrophy, insulin resistance.
Monitor injection sites for local reactions. Glycosylated Hgb level should be
monitored. Assess if pt experiencing nausea and vomiting.

Intravenous : EVERY 8
HOURS (3 times per day)

atorvastatin (LIPITOR)
tablet 10 mg : Dose 10
mg : Oral : NIGHTLY AT
BEDTIME

Lipid-lowering
agents, statins,
HMG-CoA
Reductase Inhibitors

insulin lispro (humaLOG)

injection 2-10 Units :
Dose 2-10 Units :
Subcutaneous : BEFORE
MEALS AND AT BEDTIME

Pancreatic hormone;
Antidiabetic

Lowers blood glucose

levels

0.9 % sodium chloride

1,000 mL bolus : Dose
1,000 mL : 1,000 mL/hr :
Intravenous : ONCE

fluid and electrolyte

replenishment

To replace fluids when

patients are not able to
drink enough fluids; To
replenish fluids and
sodium chloride during
periods of dehydration

Adverse effects: Redness, pain, or swelling at the injection site may occur,
swelling hands/ankles/feet, trouble breathing, muscle cramps/weakness.
Check visually for particles or discoloration and expiration date. Sodium
Chloride Injection, USP should be used with great care, if at all, in patients
with congestive heart failure, severe renal insufficiency, and in clinical states
in which there exists edema with sodium retention. If an adverse reaction
does occur, discontinue the infusion & evaluate the patient.

ondansetron (ZOFRAN)
injection 4 mg : Dose 4
mg : IV Push : ONCE

Antiemetic and
selective 5-HT3
receptor antagonist

Decrease nausea,
reducing the urge to
vomit

Adverse Reactions: constipation, dry mouth and throat, painful or difficult

urination, urine retention, impotence, visual and auditory disturbances.
Assess pts condition before therapy and regularly thereafter.

0.15 mg/kg over 15

min

anticoagulant

5000 units SC q812hr

Reduce the ability of the

blood to clot

Anticoagulant

2-5 mg PO/IV qDay

for 2 days, OR 10
mg PO for 2 days
in healthy
individuals

Treat
thromboembolism,
prevention of pulmonary
embolism caused by
DVT.

Analgesics,
antipyretic

325-650 mg PO/PR
q4hr PRN, or 1000
mg PO q6-8hr
PRN; not to exceed
4 g/day

Pain, Fever, for oral

temp above 100.4
degrees Fahrenheit or
mild pain

atropine 0.1 mg/ mL

injection 0.5-1 mg : PRN
Dose 0.5-1 mg :
Intravenous : AS NEEDED

Anticholinergic
agents, ophthalmic;
anticholinergic,
antispasmodic agent

0.5-1 mg or 0.04
mg/kg IV q5min, no
more than 3 mg

Bradycardia, for
symptomatic
Bradycardia (below 60
beats/min and BP
below 90 systolic)

dextrose (GLUTOSE) 40
% 1 tube = 37.5 grams
gel = 15 grams Dextrose
15 g : PRN Dose 15 g :
Oral : AS NEEDED
dextrose 50 % (D50W)

Glucose-elevating
agent

4-20 g

Low blood sugar

Glucose-elevating

10-25 g

Low blood sugar

heparin (porcine)
injection 5,000 Units :
Dose 5,000 Units :
Subcutaneous : EVERY 8
HOURS (3 times per day)

warfarin (COUMADIN)
tablet 2.5 mg : Dose 2.5
mg : Oral : DAILY AT
1700
2.5 mg on Monday,
Friday 5MG rest of the
days
acetaminophen
(TYLENOL) tablet 325650 mg : Dose 325-650
mg : Oral : EVERY 4
HOURS PRN
OR
acetaminophen
(TYLENOL) suppository
325-650 mg : Dose 325650 mg : Rectal : EVERY
4 HOURS PRN :

Risk for bleeding increases when pt takes NSAIDs and antiplatelet drugs.
PTT is maintained within therapeutic range to prevent adverse reactions.
Common adverse effect is bleeding (can be recersed easily by protamine
sulfate), bruising, hematoma formation, necrosis of skin and
thrombocytopenia. Assess for bleeding and pts underlying condition before
therapy. Monitor VS, Hgb level, Hct, platelet count, PT, INR, and PTT.
Assess pts urine, stool, emesis for blood.
Diet high in Vitamin K reduces effectiveness of the drug. Adverse effect is
minor bleeding. Monitor for adverse reactions such as hemorrhage,
prolonged clotting time, rash, fever, diarrhea, hepatitis. Inspect pt for
bleeding, gums, bruises, petechiae, epistaxis, tarry stools, hematuria, and
hematemesis. Monitor PT regularly. Carefully monitor PT and INR values.
Keep vitamin K available,to treat frank bleeding caused by warfarin.
May slightly increase effects of oral anticoagulants such as warfarin and
thrombolytic drugs. Risk for liver toxicity is increased with chronic alcohol
use, Other adverse reactions include skin rash, hypoglycemia, neutropenia.
Assess pts level of pain and inflammation before therapy begins and
evaluate drug effectiveness after administration.
Monitor for adverse reactions such as headache, tachycardia, restlessness,
dizziness, blurred vision, dry mouth, urinary hesitancy, & constipation;
Monitor VS, cardiac rhythm, urine output, vision for signs of impending
toxicity; provide stool softeners as ordered for constipation. Contraindicatedglaucoma, myasthenia gravis, prostatic hyperplasia, reflux esophagitis, and
GI obstructive disease. Have emergency equipment available to treat new
cardiac arrhythmias. Provide lozenges and frequent mouth care for dry
mouth.

syringe 25 mL : PRN
agent
Dose 25 mL :
Intravenous : AS NEEDED
glucose chewable tablet Glucose-elevating
12 g : PRN Dose 12 g :
agent
Oral : AS NEEDED

Antidysrhythmics
lidocaine (XYLOCAINE)
injection 50-100 mg :
PRN Dose 50-100 mg :
Intravenous : AS NEEDED

4-20 g

Low blood sugar

1-1.5 mg/kg slow

IV bolus over 2-3
minutes

to abolish sustained or
symptomatic
Ventricular Tachycardia

Monitor for adverse effects such as confusion, tremor, restlessness,

seizures, hypotension, new arrhythmias, cardiac arrest, tinnitus, blurred
vision, respiratory depression, and anaphylaxis. Monitor serum lidocaine
levels for toxicity, electrolyte, BUN, and creatinine levels. Assess pt
arrhythmias, monitor ECG continuously when therapy starts. Monitor pts VS.
Measure apical pulse rate and blood pressure before giving the drug.